SCOPE OF PROTEINS ISOLATED FROM BACILLUS SP. AS A POTENTIAL WEAPON AGAINST ANTIBIOTIC RESISTANCE

Antibiotic resistance is a growing global health crisis, threatening the effectiveness of many life-saving treatments. As infections increasingly resist traditional antibiotics, there is an urgent need for innovative solutions. This review focuses on the potential of Bacillus-derived proteins to address this challenge. Bacillus species, known for their resilience and versatility, have been historically used in biotechnology, especially for antibiotic production. Recent studies have shown that proteins from Bacillus, such as bacteriocins and lytic enzymes, have significant antimicrobial properties. These proteins disrupt bacterial cells by breaking down cell walls, interfering with DNA processes, and other mechanisms, making them strong candidates against drug-resistant bacteria. The review also explores the production and enhancement of these proteins using advanced biotechnological methods, as well as their potential role in combination therapies with existing antibiotics to overcome resistance. However, developing these Bacillus proteins into marketable drugs comes with challenges, including ensuring their safety, navigating complex regulatory pathways, and conducting thorough clinical trials. By synthesizing current research and presenting relevant case studies, the review underscores the potential of Bacillus proteins in revolutionizing infection treatment and combating antibiotic resistance. Despite the challenges, these proteins represent a promising frontier in the development of next-generation antibiotics, offering a new, effective, and sustainable approach to treating resistant infections. As the global health community faces the rising threat of antibiotic resistance, Bacillus-derived proteins could lead the way toward more effective treatments, marking a significant advancement in global health and pharmaceutical biotechnology.